Company announcement 02/2023.

Roskilde, April 11. 2023

Apillet ApS, a Danish biotech company, develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals, today announces the identification of a commercially available cellulase for its APIVault encapsulation material.

We are thrilled to announce that we have found a cellulase enzyme that meets our criteria for the APIVault encapsulation technology. Such a cellulase is crucial for creating the APIVault two-component material that can release drugs or other substances at specific locations in the gastrointestinal tract. The enzyme can degrade cellulose, which is the main component of our APIVault material, in a controlled manner. This allows us to tailor the release profile of our encapsulations according to the needs of different applications. Whether it is for delivering biopharmaceuticals, sensitive pharmaceuticals, probiotics, or nutraceuticals, the APIVault technology offers a natural and effective solution that protects the active ingredients from the harsh environment of the stomach and delivers them where they are most needed. The cellulase comes from a reputable commercial vendor. We are excited about this breakthrough and look forward to sharing more details about our APIVault technology soon.

Apillet is currently defining continued development work and is actively looking for additional investments or pharma collaborations for the development of APIVault.

About APILLET ApS

Apillet ApS is a biotech company based in Roskilde Denmark, that develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals.

Further information:

CEO Anders B. Christensen, cell +45 5178 0684, email: anders.christensenapillet.com

CFO Carsten L. Petersen, cell +45 2346 2718, email: carsten.petersenapillet.com